Drugs / Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution
Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07082816 | Sep 2025 → Apr 2026 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07082816 ↗ |
| Route | Topical | “One drop of netarsudil 0.01%/latanoprost 0.005% ophthalmic solution in each eye in the evening for three months” NCT07082816 ↗ |